A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
Year: 2022
Type: article
Study design: Clinical Trial
Abstract: Purpose This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of bendamustine in patients with previously untreated indolent B-cell non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL) (Group 1) and patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) (Group 2). Methods Rituximab 375 mg/m2 was administered intravenously every 28 days to Group 1 patients on day 1 and every 21 days to Group 2 patients on day 1. Bendamustine 90 mg/m2/day was administered to the former on days 1 and 2; bendamustine 120 mg/m2/day was administered to the latter on days 2 and 3. Each regimen was delivered up to six cycles for both groups. The primary endpoints were safety and tolerability in Groups 1 and 2, respectively. Results Among 37 enrolled patients, safety was assessed in 36. In Group 1 (n = 30), 27 patients (90%) had follicular lymphoma. Adverse events (AEs) were observed in all 30 patients in Group 1. Dose-limiting toxicities were observed in two of six patients in Group 2. Common AEs included lymphocyte count decreased (86.7%, 100%). In Group 1, overall response and complete response rates were 93.1% (95% confidence interval [CI] 77.2–99.2%) and 75.9% (95% CI 56.5–89.7%), respectively. The Cmax and AUC of bendamustine tended to be higher in Group 2 than in Group 1. Conclusions This study showed that bendamustine is safe, well-tolerated and effective for patients with previously untreated iNHL, MCL or rrDLBCL. Pharmacokinetic data were equivalent to those obtained outside of Japan. Registration numbers Registration NCT03900377; registered April 3, 2019.
Authors: Kenichi Ishizawa, Masahiro Yokoyama, Harumi Kato, Kazuhito Yamamoto, Masanori Makita, Kiyoshi Ando, Yasunori Ueda, Yoshimichi Tachikawa, Youko Suehiro, Mitsutoshi Kurosawa, Yoshihiro Kameoka, Hirokazu Nagai, Nobuhiko Uoshima, Takayuki Ishikawa, Michihiro Hidaka, Yoshikiyo Ito, Atae Utsunomiya, Koji Fukushima, Michinori Ogura
Institutions: Yamagata University Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Aichi Cancer Center, Okayama Medical Center, Tokai University Hospital, Kurashiki Central Hospital, National Hospital Organization Kyushu Cancer Center, Sapporo National Hospital, Akita University Hospital, Nagoya Medical Center, Japanese Red Cross Society Kyoto Daini Hospital, Kobe City Medical Center General Hospital, Kumamoto Medical Center, Imamura Hospital, SymBio Pharmaceuticals Limited (Japan), Kasugai Municipal Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,860
Funders: Scientific and Research Department, Plovdiv University 'Paisii Hilendarski', Amgen, Micron Technology, Bristol-Myers Squibb, Pfizer, AstraZeneca, Bayer, Novartis, Sanofi, Celgene, AbbVie, Takeda Pharmaceutical Company, Celltrion Healthcare, Incyte, Nippon Shinyaku, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Eisai, Kyowa Hakko Kirin, Meiji Seika Pharma, Astellas Pharma, Otsuka Pharmaceutical, Teijin Pharma, Yakult Honsha, Ono Pharmaceutical, SymBio Pharmaceuticals Limited, Chugai Pharmaceutical, MSD K.K., Janssen Biotech, Genmab, JIMRO, Mundipharma
OpenAlex ID: W4284880971
